Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed

This publication has 26 references indexed in Scilit:

• Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment
  Clinical Cancer Research, 2010
• Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation
  Cancer and Metastasis Reviews, 2010
• KRAS Mutation
  The Journal of Molecular Diagnostics, 2010
• Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
  Journal of Clinical Oncology, 2009
• Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies
  Journal of Clinical Oncology, 2009
• Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
  New England Journal of Medicine, 2009
• Therapeutics by Cytotoxic Metabolite Accumulation: Pemetrexed Causes ZMP Accumulation, AMPK Activation, and Mammalian Target of Rapamycin Inhibition
  Cancer Research, 2009
• The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL
  Blood, 2009
• Molecular basis of antifolate resistance
  Cancer and Metastasis Reviews, 2007
• Checking the Cox model with cumulative sums of martingale-based residuals
  Biometrika, 1993